NIH Director's New Innovator Award (DP2 Clinical Trial Optional)
Forecasted Federal grant Posted
- Opportunity number
- RFA-RM-28-002
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- $475,000
Opportunity facts
- Expected posting
- Assistance listings
-
- 93.310 Trans-NIH Research Support
- Funding instrument
- Grant
- Category
-
- Health
- Eligible applicants
-
- County Governments
- Higher Education Inst. (Public)
- Small Businesses
- Other
- Higher Education Inst. (Private)
- Tribal Organizations (Not Federally Recognized)
- City/Township Governments
- Special District Governments
- Independent School Districts
- Non-501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- State Governments
- For Profit Organizations
- Public or Indian Housing Auth.
- 501(c)(3) Nonprofits
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institutes of Health is forecasting applications for the NIH Director's New Innovator Award (DP2 Clinical Trial Optional), a grants program supporting exceptionally creative early-stage investigators pursuing bold, innovative research across all fields relevant to the NIH mission, with an application due date in September–October 2026.
The award is open to a broad range of applicants including 501(c)(3) and non-501(c)(3) nonprofits, higher education institutions (public and private), small businesses, for-profit organizations, state and local governments, tribal governments (federally recognized and not federally recognized), U.S. territories and possessions, faith-based or community-based organizations, regional organizations, eligible federal agencies, and non-domestic (non-U.S.) entities. The program complements other NIH early-stage investigator programs and is part of the NIH Common Fund's High-Risk, High-Reward Research Program.
Awards are made under CFDA 93.310 (Trans-NIH Research Support), which covers biomedical and behavioral research across the full spectrum of scientific disciplines within the NIH mission. Scientific merit review encompasses significance, approach, and innovation of the proposed research; competency of the principal investigator; adequacy of resources and environment; budget and period of support; and where applicable, measures for protecting against adverse effects. Funding decisions are based on scientific merit and program relevance, with review by a scientific review group and national advisory council or board. The review cycle typically spans four to nine months.
Almost all awards are made for at least one year, with additional support up to four more years depending on scientific review group and national advisory council recommendations, successful annual performance, and fund availability. Grantees must retain financial and programmatic records for three years from the date the annual financial status report is submitted, subject to audit requirements under OMB 2 CFR 200 and 45 CFR 75, Subpart F.
Forecast synopsis
The NIH Director's New Innovator Award supports exceptionally creative early-stage investigators pursuing bold, innovative research with the potential to transform important areas of science relevant to the NIH mission. Applications are welcome across all fields relevant to NIH. The award complements other NIH programs that support early-stage investigators and is part of the NIH Common Fund's High-Risk, High-Reward Research Program.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity